Hester Biosciences shares surged over 15% on Friday following the release of its robust Q1 FY26 earnings. The company posted a sharp improvement in profitability, with net profit more than doubling year-on-year. As of 12:29 PM, the shares were trading 15.69% higher at Rs 2,255.00
In Q1 FY26, Hester reported a consolidated profit after tax (PAT) of ₹17.30 crore, up 131% from ₹7.49 crore in the same quarter last year. Revenue from operations came in at ₹84.11 crore, marking a modest 2% growth compared to ₹82.27 crore in Q1 FY25.
Segment-wise, the company’s Africa operations were the standout performer, delivering revenue of ₹17.23 crore, a massive 516% jump from ₹2.80 crore a year ago. In contrast, Hester Nepal reported a 20% decline in revenue to ₹5.08 crore.
Operationally, EBITDA rose 33% YoY to ₹26.18 crore, with margins expanding to 31% from 24% in the prior-year quarter. Gross profit stood at ₹61.64 crore, up 5% year-on-year.
The company’s earnings per share (EPS) for the quarter stood at ₹20.33, compared to ₹8.80 in Q1 FY25, reflecting the sharp rise in profitability.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
